

Uni-Bio, Ypsomed to develop diabetes and osteoporosis products

05 May 2020 | News

Collaboration between Uni-Bio Science Group and Swiss company Ypsomed co-develops an innovative pre-filled injection pen for Uni-Bio's pipeline products



A fully integrated biopharmaceutical company -- Uni-Bio Science Group Limited announced that its wholly-owned subsidiary Beijing GeneTech Pharm reached a partnership with Swiss company Ypsomed, to co-develop an innovative pre-filled injection pen for Uni-Bio's pipeline products. According to the agreement, Ypsomed's YpsoPen® drug delivery platform will be developed for Beijing BKJ's glucagon-like peptide-1 (GLP-1) agonist ("Uni-E4") and parathyroid hormone (PTH) analogue ("Uni-PTH"), which are two new biologic products indicated for the treatment of diabetes and osteoporosis, respectively. Thereafter, Beijing BKJ will be responsible for further clinical trial development and will share YpsoPen® related clinical trial information with Ypsomed. YpsoPen® is already an approved product with the Chinese NMPA, and widely used with insulin-related products from PRC's largest insulin producers. Considering 30% share of diabetes market uses domestic-made insulin in PRC, YpsoPen® is extremely reliable and highly recognized by Chinese patients and doctors. The group will be the first company in China to launch GLP-1 and PTH product with YpsoPen®. Both products require long-term administration, and therefore the integration with YpsoPen® will provide patients with a safer long-term self-care solution.

Comparing to other injector pen products in China, YpsoPen® is an intuitive variable dose pen injector with several advantages, including fulfilling ISO 11608-1:2014 requirements for dose accuracy, equipping with efficient state-of-the-art delivery mechanics with gearing, ensuring correct dosing up to the last drop. As a business partner in China of Ypsomed, the group expects the partnership will considerably drive up its product value. Ypsomed has other exciting self-care injection platform products, such as automatic pen injector systems, wearable large-volume patch injector systems and Bluetooth intelligent injection system (both in development). As the Group strives toward its vision of becoming a leader in the treatment of chronic disease in China, Ypsomed's range of self-care solutions are complementary to the Group's future development plan and there is a large opportunity for both companies to further extend the collaboration.

Referring to the collaboration, Mr. Kingsley Leung, the Chairman of Uni-Bio Science Group said, "We have performed

extensive market research and due diligence on the pen injector market. In the end, we chose Ypsomed's solution based on their product's reliability and market acceptance. From the beginning of our development journey of Uni-E4 and Uni-PTH, our aims were to provide patient-centric products. The integration of our products with YpsoPen® not only create a greater technological hurdle against competition, most importantly it brings more convenient administration for clinical practitioners and patients. I believe the partnership doesn't stop with YpsoPen®, we hope to integrate our products in other innovative injector systems from Ypsomed, as long as they can benefit the Chinese patients."

Image Caption: Ypsomed's YpsoPen® and the Group's 2nd generation Uni-PTH (rhPTH [1-34] in cartridges for injection devices)